![Katie Hewson Katie Hewson](/sites/default/files/styles/team/public/team/Hewson_Katie_CROP_A_0.jpg?itok=fJ_l9UcW)
![Jenna Franklin Jenna Franklin](/sites/default/files/styles/team/public/team/Franklin_Jenna_HUB_3.jpg?itok=LG3e7eyO)
![Nic McMaster Nic McMaster](/sites/default/files/styles/team/public/team/McMaster_Nic_hub_0.jpg?itok=sxJgQMFQ)
![Mark Lewis Mark Lewis](/sites/default/files/styles/team/public/team/Lewis_Mark_HUB.jpg?itok=L-njn7hu)
![Katherine Liu Katherine Liu](/sites/default/files/styles/team/public/team/Liu_Katherine%20_CROP_0.jpg?itok=zEK9zUAa)
![Boriana Guimberteau Boriana Guimberteau](/sites/default/files/styles/team/public/team/Guimberteau_Boriana_CROP.jpg?itok=xIlFQPXR)
In an era where the influence of Artificial Intelligence (AI) is rapidly expanding, staying ahead of regulatory developments is crucial. With the forthcoming EU AI Act and ongoing legislative efforts in the UK and other major jurisdictions, understanding AI and its legal landscape has never been more vital. Our law firm is uniquely positioned to guide you through these complexities with our extensive expertise and forward-thinking approach.
At our law firm, we understand the importance of having legal advisers who are not only knowledgeable but also visionary. We pride ourselves on anticipating future changes and challenges in the field of AI, helping you navigate the intricate web of regulations surrounding disruptive technologies.
Our pragmatic and scalable advice, delivered through our international network, has supported clients across various AI-related projects. From technology development to strategic governance and legal compliance, our technology team offers comprehensive guidance.
Here are some of the cutting-edge AI technologies and services we specialise in:
Advised on a wide-ranging data protection review for NASDAQ-listed Exscientia (an AI drug discovery company).
Advised on its recent strategic collaboration with Merck, using BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates – initially for three targets in oncology, neurology and immunology – and to identify and develop innovative compounds through Hit Identification to pre-clinical stage.
Advised a household name on its use of generative AI in direct marketing, in particular its production of highly personalised ads for consumers, including children.
Advised a Hong Kong-based business AI and automation platform - on its proposed reverse merger and listing on NASDAQ.
Advised the global private equity advisory firm on building their AI governance framework including the upcoming legal and regulatory obligations that they may be subject to under the EU AI Act.
Advised on the acquisition of AI-enabled products and the negotiation of appropriate terms considering the risks associated with the use of generative-AI, including protections with respect to the use of customer data for ongoing training of the AI-tools, copyright and intellectual property issues and reliability and liability issues.
Advised on IT service contracts, including the procurement of innovative AI software for digitising private equity structures and outsourced processing of regulatory documentation. We also ensured the client fully understood the AI products being acquired and that key risks were effectively managed under the contract.
Advised an AI start-up with an estimated €2 billion valuation, on the purchase and implementation of a cloud-based enterprise management software necessary to streamline enterprise functions within the company and set it on a course for continued growth as it continues its rapid expansion.